BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CNS Disease Analysis: Epilepsy

January 08, 2020

The breadth of each epilepsy drug’s product label is highly pertinent to its competitive edge and provides impetus for the ongoing uptake of branded anti-epileptics. Even in the saturated partial-onset seizures (POS) market, numerous label expansions broadening POS drug usage to monotherapy use and the treatment of pediatric patients are likely to bolster uptake. Further expansion to generalized and secondary generalized seizures, specific subpopulations such as refractory epilepsy patients, and rare pediatric epilepsy patients may also help to maximize commercial potential.

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Dravet Syndrome (Epilepsy)
Infantile Spasms (West Syndrome; Epilepsy)
Lennox-Gastaut Syndrome (LGS; Epilepsy)
Partial Seizures (Epilepsy)
Seizure Disorders (Epilepsy)
Back to the top Back to the top